TG Therapeutics (TGTX) had its “Buy” rating reiterated at HC Wainwright

TG Therapeutics (NASDAQ:TGTX – Get a Free Report)The stock had its “buy” rating restated by HC Wainwright in a report on Wednesday, Benzinga reports. They currently have a $49.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 93.83% from the stock’s previous close.

Other equities analysts have recently issued research reports on the company. B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Goldman Sachs Group boosted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $31.83.

See the latest stock report on TGTX

TG Therapeutics trading rose 0.8%

Shares of NASDAQ:TGTX traded up $0.20 during trading on Wednesday, reaching $25.28. 1,970,327 shares of the company traded hands, compared to its average volume of 3,624,379. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 109.91 and a beta of 2.21. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83, and a debt-to-equity ratio of 0.58. The company’s fifty day moving average is $21.73 and its 200 day moving average is $18.15.

TG Therapeutics (NASDAQ:TGTX – Get Free Report ) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company’s revenue for the quarter was up 357.0% on a year-over-year basis. In the same quarter last year, the company earned ($0.34) earnings per share. As a group, analysts anticipate that TG Therapeutics will post 0.13 EPS for the current year.

Institutional investors are weighing in on TG Therapeutics

Institutional investors have recently modified their holdings of the business. Pingora Partners LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at $27,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics in the second quarter valued at $35,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at $58,000. nVerses Capital LLC boosted its position in shares of TG Therapeutics by 34.9% in the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Quarry LP boosted its position in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 503 shares in the last quarter. 58.58% of the shares are held by hedge funds and other institutional investors.

TG Therapeutics Company Profile

(Get a free report)

TG Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the acquisition, development and commercialization of novel treatments for B-cell-mediated diseases in the United States and internationally. It offers BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and secondary active progressive disease in adults.

See Also

Get news and reviews for TG Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TG Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.